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Lung transplantation is a lifesaving therapy for people living with severe, life-threatening lung disease. The high mortality rate
among patients awaiting transplantation is mainly due to the low percentage of lungs that are deemed acceptable for
implantation. Thus, the current shortage of lung donors may be significantly reduced by implementing different therapeutic
strategies which facilitate both organ preservation and recovery. Here, we studied whether the anti-inflammatory effect of
human umbilical cord-derived mesenchymal stem cells (HUCPVCs) increases lung availability by improving organ
preservation. We developed a lung preservation rat model that mimics the different stages by which donor organs must
undergo before implantation. The therapeutic schema was as follows: cardiac arrest, warm ischemia (2 h at room temperature), cold
ischemia (1.5 h at 4°C, with Perfadex), and normothermic lung perfusion with ventilation (Steen solution, 1 h). After 1 h of warm
ischemia, HUCPVCs (1 × 106 cells) or vehicle was infused via the pulmonary artery. Physiologic data (pressure-volume curves) were
acquired right after the cardiac arrest and at the end of the perfusion. Interestingly, although lung edema did not change among
groups, lung compliance dropped to 34% in the HUCPVC-treated group, while the vehicle group showed a stronger reduction (69%,
p < 0 0001). Histologic assessment demonstrated less overall inflammation in the HUCPVC-treated lungs. In addition, MPO
activity, a neutrophil marker, was reduced by 41% compared with vehicle (p < 0 01). MSC therapy significantly decreased tissue
oxidative damage by controlling reactive oxygen species production. Accordingly, catalase and superoxide dismutase enzyme
activities remained at baseline levels. In conclusion, these results demonstrate that the anti-inflammatory effect of MSCs protects
donor lungs against ischemic injury and postulates MSC therapy as a novel tool for organ preservation.
1. Introduction
Lung transplantation has become the standard treatment for
end-stage respiratory diseases. Although there is an increase
in the number of annual lung transplants, the mortality on cur-
rent waiting lists can be as high as 30% due to the shortage of
organs available for transplantation [1, 2]. Several factors are
responsible for this deficit. First, there is a low number of multi-
organ brain death donors available. Second, only about 15% of
lungs from these donors are suitable for transplantation as
most of them are discarded due to injuries caused by brain
death and/or poor donor management [3]. Third, transplant
programs are usually very conservative in the selection of
donor lungs to avoid severe complications associated with pri-
mary graft dysfunction (PGD). PGD is the end result of a series
of injuries occurring in the donor organ from the time of death
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to reperfusion in the recipient [4]. Hence, the incidence of PGD
is directly related to processes of sterile inflammation that
occur in the lung transplantation setting, such as ischemia,
ischemia-reperfusion injury (IRI), and mechanical ventilator-
induced injury [5]. All these processes cause an increase in
the production of reactive oxygen species (ROS) and the conse-
quent cellular damage. Thus, oxidative stress plays a key role in
the development of donor lung injury, which is mainly charac-
terized by edema, ineffective gas exchange, increased levels of
proinflammatory cytokines, and pulmonary infiltrates [6, 7].
In fact, early neutrophil extravasation into the alveolar space
and the formation of neutrophil extracellular traps produce
lung damage in both IRI and PGD [8]. Recent data suggest that
neutrophil recruitment is mediated by ROS-activated alveolar
macrophages andmonocytes [9]. In addition, ROS can activate
antigen-presenting cells that trigger the adaptive immune
response leading to organ rejection [10]. Thus, the strong asso-
ciation between PGD and lung allograft rejectionmay be linked
by ROS and alveolar macrophages [11].
In order to solve the existing organ shortage, it is imperative
not only to increase the organ procurement, but also to ensure
the good quality of the retrieved lungs by adopting new thera-
peutic approaches which better preserve those organs. At pres-
ent, several strategies are being used, including improvement in
donor lung preservation, use of organs from donors with exten-
ded/marginal characteristics such as cardiac death donors
(DCD), and normothermic ex vivo lung perfusion (EVLP) to
assess and repair injured donor lungs [12]. Some of these strat-
egies may also benefit from the use of gene and stem cell ther-
apy, which have demonstrated therapeutic potential for solid
organ graft optimization. In this context, human interleukin-
(IL-) 10, a potent anti-inflammatory cytokine, has been shown
to reduce IRI and improve graft function when administered
through the transtracheal route prior to donor lung retrieval
[13]. More recently, IL-10 gene therapy delivered in an EVLP
system demonstrated improved lung function in a pig model
of lung transplantation [14]. Similarly, mesenchymal stem
cell (MSC) therapy has been shown to be safe and effective
for the recovery of damaged lungs when administered during
EVLP [15, 16] and also for the treatment of IRI in kidney, liver,
heart, and lung transplantation [17–19]. Additionally, MSC
therapy was able to reduce inflammatory responses in a mouse
model of LPS-induced acute lung injury [20]. However,
whether MSC therapy improves donor lung preservation has
not been previously studied. As MSCs demonstrated immuno-
modulatory and anti-inflammatory properties, we hypothesized
that the administration of MSCs during the warm ischemia
period may better preserve the donor organ by preventing lung
inflammation and limiting, in consequence, further injuries
related to ischemia and reperfusion.
The umbilical cord has become an attractive and readily
available source of MSCs [21]. Human umbilical cord peri-
vascular cells (HUCPVCs) are isolated from neonatal tissue
and present higher levels of stromal progenitors and prolifer-
ation capacity than bone marrow-derived MSCs [22]. Thus,
HUCPVCs are being used as a rich source of MSCs for cell
replacement therapy in preclinical and, more recently, clini-
cal studies [21]. In fact, HUCPVCs demonstrated improved
regenerative properties for acute myocardial infarction [23]
and bone repair [24]. In this study, we investigated whether
the local infusion of HUCPVCs during donor lung ablation
increases lung availability by improving organ preservation.
For this purpose, we developed a donor lung preservation
rat model that mimics the different phases by which donor
organs must undergo before implantation. We found that
HUCPVCs protect donor lungs against ischemic injury by
reducing oxidative damage and neutrophil extravasation into
the lung tissue. More importantly, HUCPVC therapy signif-
icantly conserved lung function during ischemia and, thus,
represents a novel tool for donor lung preservation.
2. Materials and Methods
2.1. HUCPVC Culture. HUCPVCs were gently provided at
passage 2 by Dr. Mazzolini (Laboratory of Gene Therapy,
IIMT, CONICET-Universidad Austral). HUCPVCs were
cultured in DMEM low-glucose medium supplemented with
10% (v/v) of fetal bovine serum (FBS, Gibco), 100U/ml pen-
icillin, and 100 μg/ml streptomycin (Gibco) at 37°C in a
humidified incubator containing 5% CO2. The medium was
replaced every 2–3 days, and HUCPVCs were subcultured
at 70–90% confluence until passage 4-6 cells were obtained
[23]. HUCPVCs were characterized according to the Interna-
tional Society for Cellular Therapy (ISCT) guidelines [25].
MSC surface-specific markers (CD14, CD34, CD44, CD73,
CD90, and CD105 all from BD Biosciences) were determined
by flow cytometry (FACSCalibur flow cytometer, Becton
Dickinson), and data acquired were analyzed using FlowJo
software (Tree Star).
2.2. Donor Lung Preservation Rat Model. All the procedures
conformed to the US National Institute of Health’s guidelines
for the care and use of laboratory animals with approval
from the Animal Care and Use Committee of the Favaloro
University (CICUAL-UF). Twelve-week-old male Wistar
rats (285 ± 27 g) were obtained from Facultad de Ciencias
Veterinarias, Universidad Nacional de La Plata. Anesthesia
was induced using an intraperitoneal injection of 60mg/kg
ketamine and 5mg/kg xylazine. Heparin (1000U/kg) was
administered intrahepatically and allowed to circulate for
5min. Animals were then euthanized with an intrahepatic
injection of sodium thiopental solution (250mg/kg). Fol-
lowing cardiac arrest (time = 0), an endotracheal tube was
secured in the trachea and median sternotomy was per-
formed. Lungs were mechanically ventilated (SomnoSuite,
Kent Scientific) to acquire the basal pressure-volume curve.
Lungs were not flushed to remove blood and were left
untouched in the donor for 45min. Then, the entire heart-
lung block was excised, a cannula was placed in the pulmo-
nary artery (PA), and the left atrium (LA) was opened
(LA pressure = 0 cm H2O). At this point (1 h), lungs were
suspended in a humid chamber at room temperature and
randomly divided into two groups: vehicle control, receiving
1ml of Krebs-Henseleit bicarbonate buffer containing 4%
bovine serum albumin, or HUCPVCs, receiving cell therapy
(1 × 106 cells in 1ml Krebs-Henseleit solution) administered
by using a 1ml syringe via the PA. After the treatment, lungs
were kept at room temperature for another hour. In total,
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lungs underwent 2h of warm ischemia without mechanical
ventilation. Lungs were then infused via the PA
(PApressure < 15 cm H2O) with 10ml of cold preservation
solution (Perfadex) and kept at 4°C for 90min. After the cold
ischemia period, ungs were rewarmed to room temperature
and perfused through the PA with Steen solution alone for
1h (PApressure < 15 cm H2O, perfusion rate = 2ml/min).
The temperature of the perfusate was gradually increased from
room temperature to 37°C for approximately over 30min. The
perfusion was continued at 37°C until reaching 60min. During
EVLP, lungs were mechanically ventilated starting with a short
alveolar recruitment strategy which included a gradual
increase in both the positive end-expiratory pressure (PEEP)
up to 8 cm H2O and the respiratory rate from 20 to 60 breaths
per min. Ventilation was continued using a peak airway pres-
sure (PAWP) of 15 cm H2O, a PEEP of 2 cm H2O, and a respi-
ratory rate of 60 breaths per min. Lung functional data
(pressure-volume curve) were acquired at the end of the perfu-
sion (60min time point). A graphical guide of the surgical pro-
cedure is available as Supplementary Material (available here).
2.3. Pressure-Volume Curves and Lung Compliance
Determination. Measurements were performed in the iso-
lated lungs by using a small animal mechanical ventilator
(SomnoSuite, Kent Scientific) (Figure S1). The pressure-
volume (P-V) curves were obtained using the regular pres-
sure ramp approach up to a maximal tidal volume of
10ml/kg to avoid lung overdistension. Briefly, lungs were
inflated to a given pressure (PAWP of 4, 8, 12, and 16mm
H2O were applied), and the tidal volume reached at each
pressure step was measured. This method is based on the
single-compartment linear model, in which the P-V relation-
ship corresponds to a straight line and a single value
describes the compliance. The tidal volume in ml/kg was
plotted against the pressure difference between the PAWP
and PEEP. Lung compliance was calculated from the slope
of the linear regression model [26].
2.4. CFSE Cell Staining and Flow Cytometry.HUCPVCs were
harvested, resuspended in PBS at 2 × 106 cells/ml, and incu-
bated with 2.5 μM carboxyfluorescein diacetate succinimidyl
ester (CFSE, eBioscience) for 5min. Cells were then washed
and resuspended in culture medium for 5min at 37°C to
stabilize the CFSE staining. After a final wash step, cells
were plated at a density of 4,000 cells/cm2 and cultured for
48 h. CFSE staining was confirmed by using fluorescence
microscopy and flow cytometry. To determine the presence
of donor cells in the lungs, CFSE-labeled HUCPVCs were
infused through the pulmonary artery as described above
(see Section 2.2). At the end of the experiment, samples were
obtained from different sections of the left lung (upper, mid-
dle, and lower sections). Lung samples were then minced
with scalpels, incubated in Hank’s balanced salt solution
containing 1mg/ml collagenase type 2 (Worthington Bio-
chemical Corp.) for 30min, and passed through 40 μmnylon
mesh to obtain a single-cell suspension. Data from three
independent experiments were acquired in a FACSCalibur
flow cytometer (Becton Dickinson) and analyzed using
FlowJo software (Tree Star).
2.5. Histological Examination and Immunostaining. For
histopathological examination, lung biopsies were taken
at the end of the perfusion. Lung tissue was fixed in 10%
neutral-buffered formaldehyde for 48 h, embedded in paraf-
fin, and sectioned. Sections (5 μm thick) were stained with
hematoxylin-eosin and examined at a ×200 magnification.
To determine the extent of lung injury, we considered (i)
alveolar septal thickening, (ii) cellular infiltration, and (iii)
atelectasis/collapse. Scoring was done by a pathologist who
was blinded to the experimental groups. An injury score of
0–3 (0= absent/none, 1 =mild, 2 =moderate, and 3= severe)
was assigned to each variable and used to calculate a total
score for lung injury. A total score of 0 indicated normal his-
topathology and a total of 9 points indicated maximal dam-
age. Immunohistochemical staining of paraffin-embedded
lung sections was performed using an automated Ventana
BenchMark GX instrument (Roche Diagnostics) according
to the manufacturer’s instructions. The presence of neutro-
phils was detected by using an anti-myeloperoxidase rabbit
polyclonal antibody (Roche Diagnostics). To determine the
presence of human donor cells in the lungs, we employed
an anti-human vimentin (V9) mouse monoclonal antibody
(Roche Diagnostics). Primary antibodies were detected by
using the iVIEW DAB detection kit (Roche Diagnostics).
Images were acquired using a Zeiss Axiophot microscope.
2.6. Quantification of Lung Wet/Dry Weight Ratio. Lung
samples were immediately weighed and then placed in a des-
iccating oven at 55°C for 72h; at that point, dry weight was
measured. The ratio of wet/dry weight was used to quantify
lung water content.
2.7. Myeloperoxidase Activity. MPO activity, an index of
polymorphonuclear leukocyte accumulation, was deter-
mined as previously described [27]. Lung tissue samples
(100-200mg) were homogenized in 1ml of a solution con-
taining 0.5% hexa-decyl-trimethyl-ammonium bromide
(HTAB) dissolved in 50mM potassium phosphate buffer
(pH 6). The suspension was sonicated and centrifuged for
30min at 20,000g at 4°C. The supernatant was assayed for
MPO activity. An aliquot of the supernatant (10μl) was
combined with 190μl of 50mM phosphate buffer (pH 6.0),
containing 0.167mg/ml o-dianisidine and 0.0005% H2O2.
Changes in absorbance at 460nm were measured spectro-
photometrically. MPO activity is expressed as μmol of
degraded peroxide per minute per mg of protein at 25°C.
2.8. Protein Extracts. Tissue samples (100-200mg) were sus-
pended in 1ml 50mM potassium phosphate buffer (pH 7.4),
containing 0.1% Triton X-100 and homogenized. Homoge-
nates were sonicated for 20 s in an ice bath. Suspensions were
centrifuged at 14,000g for 15min, and supernatants were
harvested. Protein concentrations were determined using
the Bradford micromethod assay (Bio-Rad).
2.9. Protein Carbonyl Content. Protein carbonyl content was
quantified using the 2,4-dinitrophenylhydrazine (DNPH)
alkaline method [28]. Briefly, 80 μl of DNPH (10mM in
0.5M H3PO4) was added to 80μl of protein solution, and
the mixture was incubated for 10min at room temperature.
3Stem Cells International
Forty μl of NaOH (6M) was then added. After 10min of
incubation at room temperature, absorbance was read at
450nm against a blank in which the protein solution was
substituted by an equal volume of buffer solution.
2.10. Antioxidant Enzyme Activities. Activities of the antioxi-
dant enzymes superoxide dismutase (SOD) and catalase
(CAT) were determined spectrophotometrically in tissue
homogenates. SOD assays were performed using the ribofla-
vin/nitroblue tetrazolium assay in a microtiter plate format
[29]. Twenty μl of lysate or SOD standard (0.5-500U/ml) was
measured in a final reaction mixture of 300 μl potassium phos-
phate buffer (50mM, pH 7.8) containing EDTA (0.1mM),
riboflavin (1.3μM), L-methionine (10mM), p-nitro-blue tetra-
zolium (NBT,57μM), and Triton X-100 (0.025%). Absorbance
was read at 560nm both immediately and after 10min incuba-
tion under a homogenous light field at 25°C. One unit of SOD
activity was defined as the amount of enzyme able to inhibit
the reduction of NBT by 50%. CAT activity was determined
by measuring the decrease in light absorption at 240nm in a
reaction medium containing 50mM potassium phosphate
buffer (pH 7.2) and 2mM H2O2 [30].
2.11. Statistics. Continuous variables were expressed as
mean ± standard deviation (SD). One-way analysis of vari-
ance (ANOVA) with the post hoc Tukey’s test was used
for intergroup comparisons. Individual changes in lung
compliance between baseline and perfusion were analyzed
using paired t test. A value of p < 0 05 was considered
statistically significant.
3. Results
3.1. Cell Therapy with HUCPVCs to Improve Donor Lung
Preservation. First, we analyzed the immunophenotypic
characteristics of the HUCPVCs used in this study to deter-
mine whether they conformed to the minimal criteria defin-
ing MSCs [25]. HUCPVCs highly expressed (>98%) the
stromal determinants CD44, CD90, and CD105 and were
negative (<1%) for monocyte/macrophage (CD11b), endo-
thelial (CD34), and hematopoietic (CD45) markers
(Figure 1). To test the beneficial effects of MSC therapy dur-
ing donor lung preservation, we infused the HUCPVCs via
the pulmonary artery during the procurement of the lungs
from DCD (after 1 h of cardiac arrest). The period of warm
ischemia was extended to 2 h before cold preservation with
a low potassium dextran solution (Perfadex). Finally, lungs
were perfused with Steen solution alone for 1 h using the
EVLP technique in order to acquire functional data
(Figure 2). To assess the retention of HUCPVCs in the
lung parenchyma, a series of experiments (n = 3) were car-
ried out using CFSE-labeled cells (Figure 3). More than 99%
of the HUCPVCs were effectively stained with CFSE as it can
be seen by fluorescence microscopy and flow cytometry anal-
ysis (Figures 3(a) and 3(b)). The administration of 1 × 106
CFSE-labeled HUCPVCs was associated with the detection
of CFSE-positive cells in the lungs at the end of the exper-
iments (Figure 3(c)). The majority of the HUCPVCs were
located in the upper and middle sections of the lungs, pos-
sibly due to the route of administration (via the pulmonary
artery) and the rapid retention of the human cells in the rat
microvasculature because of their size (Figure 3(c)). In fact,
the presence of large cells in the microvasculature was observed
only in hematoxylin-eosin-stained lung sections from the cell
therapy group (Figure S2). To further identify HUCPVCs in
the lungs, we performed an immunohistochemical analysis
using anti-human vimentin to specifically stain human donor
cells. We found that HUCPVCs, evidenced as large cells with
a strong-diffuse cytoplasmic staining, were mainly retained
in the lung microvasculature (Figure 3(d)). Vimentin-positive
cells were not detected in lungs receiving vehicle.
3.2. Effect of HUCPVCs on Donor Lung Inflammation and
Oxidative Stress Parameters during Organ Preservation. Each
phase of lung procurement generates different degrees of
organ injury that accumulate throughout the entire proce-
dure. The total amount of organ damage directly correlates
with the subsequent incidence of PGD. In our experimental
setting, most of the organ damage occurred during the period
of warm ischemia which was extended for up to 2 h. For con-
venience, we decided to infuse the cell therapy after 1 h of
warm ischemia. Thus, donor lungs accumulated a certain
degree of injury that allowed us to determine whether
HUCPVCs can prevent further damage. Microscopic assess-
ment of histopathologic lung injury at the end of the experi-
ments showed that lungs receiving vehicle exhibited
characteristic signs of inflammatory damage including wide-
spread alveolar wall thickening, mild interstitial edema, and
the presence of cellular infiltrates in both the interstitium
and the alveoli (Figure 4(a)). By comparison, lungs receiving
HUCPVCs also showed alveolar thickening and mild edema,
but signs of inflammation were less evident as the tissue his-
tology was more similar to untouched rat lungs (Figure 4(a)).
In addition, immunohistochemical analysis for the detec-
tion of myeloperoxidase (MPO), an enzyme contained in
primary granules of cells of the myeloid lineage (neutro-
phils in particular), demonstrated the presence of MPO-
positive cells in the alveolar wall (Figure 4(b)). As quantified
in Figure 4(c), the lung tissue in the vehicle group exhibited a
significant increase in the histological injury score compared
with untouched rat lungs (basal), whereas the administration
of HUCPVCs significantly improved the lung histological
injury score compared with the vehicle group (2 7 ± 0 9 vs.
4 9 ± 0 8, respectively; p < 0 0001). The formation of pulmo-
nary edema was assessed by lung wet/dry weight ratios. No
significant differences were observed in lung wet/dry weight
ratio between HUCPVC- and vehicle-treated groups
(5 2 ± 0 7 vs. 5 7 ± 1 1, respectively; p = n s ), and values for
wet/dry weight ratios in both groups were slightly higher
than those found for untouched rat lungs (Figure 4(d)).
The absence of edema may be related to the use of Steen solu-
tion for the perfusion of the lungs, which contains human
albumin to maintain an optimal oncotic pressure that
reduces the formation of pulmonary edema during perfu-
sion [31]. The number of MPO-positive cells retained in
the interstitium and in the alveolar wall was significantly
lower in the HUCPVC group when compared with the
vehicle group (6 ± 2 vs. 12 ± 5 MPO+ cells/field,
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respectively; p = 0 004) (Figure 4(e)). To confirm the histo-
logical observations, we quantified neutrophil retention in
the lung tissue by measuring total MPO activity. As shown
in Figure 4(f), the infusion of HUCPVCs significantly
decreased MPO activity by 41% compared with the vehicle
group (0 023 ± 0 009 vs. 0 039 ± 0 011μmol/min·mg pro-
tein, respectively; p = 0 008). Most of the neutrophils were
retained in lungs receiving vehicle as MPO values were
similar to those found in basal rat lungs without perfusion
(Figure 4(f)). These data imply that HUCPVC therapy was
effective in reducing the inflammatory response triggered
by ischemia, during the preservation of donor lungs.
ROS overproduction can damage all types of biological
molecules, and carbonyl groups are the major products of
ROS-mediated oxidation reactions. Consequently, protein
carbonyl groups have been widely used as biomarkers of oxi-
dative stress because of their relative early formation and sta-
bility [32]. As expected, we found that protein carbonyl
content significantly increased by 5.6-fold in lungs from the
vehicle group when compared with untouched rat lungs
(Figure 5(a)). Moreover, the activities of the antioxidant
enzymes SOD and CAT increased by 64% and 46% in the
vehicle group with respect to untouched rat lungs (basal),
respectively (Figures 5(b) and 5(c)). The upregulation of
SOD and CAT indicates that the cellular antioxidant enzyme
system responded to the oxidative damage in order to
restore ROS homeostasis. These data demonstrate that oxi-
dative stress occurred during the preservation of donor lungs
in our experimental setting. Interestingly, cell therapy with
HUCPVCs significantly decreased the content of carbony-
lated proteins in the lungs when compared with the vehicle














































Figure 1: Characterization of human umbilical cord perivascular cells (HUCPVCs). (a) Representative phase micrograph image of
HUCPVCs in culture. HUCPVCs display a fibroblastic morphology (×100 original magnification). (b) Surface marker expression levels in
HUCPVCs analyzed by flow cytometry. HUCPVCs highly express the stromal determinants CD44, CD90, and CD105 and are negative
for CD11b, CD34, and CD45 markers. Solid blue histograms represent cells stained with fluorescent antibodies, and isotype-matched
controls are overlaid in gray.
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proteins in lungs from the HUCPVC group was signifi-
cantly higher than in untouched rat lungs (basal). Most
of these protein carbonyl groups may be generated during
the first hour of the warm ischemia period, before the
infusion of the cells. In agreement with this notion, the
administration of HUCPVCs was able to prevent the
increase in the activities of SOD and CAT implying that
the overproduction of ROS was controlled by the therapy
(Figures 5(b) and 5(c)).
3.3. Effect of HUCPVCs on Donor Lung Function. We next
evaluated the effect of the HUCPVC therapy in donor lung
function. It has been recently reported that, in the clinical set-
ting, lung compliance and ventilatory pressures are impor-
tant parameters to evaluate graft quality after EVLP in both
controlled and uncontrolled DCD [33, 34]. Lung compliance
refers to the magnitude of change in lung volume as a result
of the change in pulmonary pressure. Here, we determined
the pressure-volume curve to assess the mechanical proper-
ties of donor lungs (Figure 6(a)). Lung compliance was
obtained from the slope of this pressure-volume curve. To
avoid biological differences between animals, we compared
the compliance of each individual lung between baseline
and the end of the perfusion period (Figure 6(b)). We found
that lung compliance was significantly reduced by 69% and
34% in the vehicle group and HUCPVC group, respectively
(Figure 6(c)). Of note, HUCPVC therapy significantly
reduced by 50% the decrease in lung compliance related to
the procedure. These data indicate that the antioxidant and
anti-inflammatory effects of MSCs led to a better preserva-
tion of the donor lung function throughout the entire
procedure.
4. Discussion
Currently, the main clinical practice for donor lung preserva-
tion is static cold storage. This procedure is mainly based on
reducing cell metabolism by storing the lungs at 4°C for an
acceptable ischemic time of less than 6h [12]. Sterile inflam-
matory processes occur during this period of anoxic ischemia
and also at the time of organ reperfusion (i.e., IRI). Increased
formation of ROS is involved in the development of lung
Warm ischemia Cold ischemia EVLP

























Figure 2: Donor lung preservation rat model. (a) Experimental study design. The procedure included cardiac arrest, warm ischemia, cold
ischemia, and normothermic ex vivo lung perfusion using Steen solution with mechanical ventilation. Ablation of the lung was performed
after 1 h of warm ischemia, and cell therapy was administered via the pulmonary artery. The lung was mechanically ventilated during
perfusion starting with a short alveolar recruitment strategy (#2). Lung functional data were acquired right after the cardiac arrest
(baseline, #1 green bar) and at the end of the perfusion (endpoint, #3 green bar). For further details, please refer to Materials and Methods
(Section 2.2). (b) Schematic diagram of the normothermic ex vivo lung perfusion step. After the cold ischemia period, the lungs were
rewarmed and perfused through the pulmonary artery (PA) with Steen solution for 1 h using an open perfusion circuit in which the left
atrium (LA) was opened. During perfusion, the lungs were mechanically ventilated. (c) Representative image of a rat lung during
perfusion. Please note the position of the PA cannula (black arrow) for the perfusion and the tracheotube (white arrow) for the
mechanical ventilation.
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injury through the activation of nuclear factor-kappa B (NF-
κB) which precedes the release of proinflammatory cytokines
[35]. Accordingly, lung preservation solutions that reduce
ROS production (i.e., low-potassium dextran) are of choice
because they have shown to decrease the incidence of PGD
[36, 37]. In this study, we demonstrated that the adminis-
tration of HUCPVCs during the warm ischemia period pre-













































































Figure 3: Retention of HUCPVCs in the lungs. (a) Representative image of CFSE-labeled HUCPVCs using fluorescence microscopy (×100
original magnification). (b) Flow cytometry analysis of CFSE-labeled HUCPVCs. (A) Dot plot for the unstained control. (B) Dot plot for
CFSE-labeled HUCPVCs showing that more than 99% of the cells were positively stained. Data are representative of three independent
experiments. (c) Detection of CFSE-labeled HUCPVCs in the lungs by flow cytometry. CFSE-labeled HUCPVCs (1 × 106 cells) were
administered via the pulmonary artery as described in Materials and Methods (Section 2.2). At the end of the experiment, samples from
the upper, middle, and lower sections of the left lung were obtained and analyzed by flow cytometry. Data are representative of three
independent experiments. (d) Identification of HUCPVCs in the lungs by immunostaining against human vimentin. Representative
images of lung tissue sections obtained at the end of the perfusion from the lungs receiving infusion of vehicle (A) or HUCPVCs (B) at
×400 original magnification (inset: ×1000 original magnification). Black arrows indicate vimentin-positive cells. Please note that vimentin-
positive cells show a diffuse cytoplasmic staining.
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preserves donor lung function. Our results suggest that
HUCPVC therapy at the moment of organ ablation may
represent a novel strategy to improve donor lung
preservation.
One of the major attributes of MSCs is their anti-
inflammatory potential, which is mainly exerted through
a paracrine mechanism. A previous report found that


























































































































Figure 4: Lung injury and inflammation during organ preservation. (a) Hematoxylin and eosin stained sections obtained at the end of the
perfusion from the lungs receiving infusion of vehicle (B) or HUCPVCs (C). Lung sections from untouched rats (basal, (A)) were used as
controls. Alveolar septal thickening and interstitial cellular infiltration were more evident in the lungs from the vehicle group. Results
show representative images from each group at ×200 original magnification (inset: ×400 original magnification). (b) Representative images
of the lung tissue sections with immunostaining against myeloperoxidase (MPO) at ×400 original magnification. MPO-positive cells
appear brown. (c) Histological injury scores of the lungs in different groups were quantified as described in Materials and Methods. Data
are expressed as mean ± S D. ∗p < 0 0001 against the basal group derived from one-way ANOVA after multiple comparisons Tukey post
hoc test. (d) Lung wet/dry weight ratios at the end of the perfusion. Data are expressed as mean ± S D. (e) Quantitation of MPO-positive
cells (from (b)). MPO-positive cells were counted in 10 visual fields/section at ×200 magnification, and the average number for each
sample was calculated. Data are expressed as mean ± S D. ∗p < 0 05 and #p < 0 0001 against the basal group derived from one-way
ANOVA after multiple comparisons Tukey post hoc test. (f) Lung myeloperoxidase (MPO) activity. Data are expressed as mean ± S D.
∗p < 0 01 against the basal group derived from one-way ANOVA after multiple comparisons Tukey post hoc test.
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inflammatory molecules which reduce infarct size in a mouse
model of acute myocardial infarction [38]. More recently,
we demonstrated that both BM-MSCs and HUCPVCs
can mediate the switch from proinflammatory to anti-
inflammatory macrophages at the infarct site [39]. More-
over, anti-inflammatory exosomes derived from MSCs pre-
vent LPS activation of RAW 264.7 macrophages and also
suppress LPS-induced inflammation in mice [40]. In this
context, cell therapy using MSCs has demonstrated thera-
peutic potential to prevent pulmonary IRI and to recover
damaged lungs during EVLP [15, 16, 19]. However, the
potential benefit of MSC therapy on donor lung preserva-
tion has not been previously studied. For this reason, in the
present study, and with the aim of maximizing donor lung
availability, we infused HUCPVCs during donor lung abla-
tion to better preserve lung function. An important evidence
of pulmonary physiological dysfunction in the clinical setting
is decreased lung compliance [41], which depends on the
elastin and collagen fibers present in the lung parenchyma
and the alveolar surface tension. Low lung compliance is a
characteristic of patients with acute respiratory distress
syndrome or pulmonary fibrosis. Typically, lung compli-
ance decreases during harvesting, preservation, and trans-
plantation of the donor organ [41]. Noteworthy, HUCPVC
administration was able to significantly reduce the loss of
lung compliance during organ preservation. This result has
an important implication in the clinical setting, as it may
increase the number of suitable lungs available for
transplantation.
There are multiple steps in the transplantation procedure
that may injure the donor lung. Organ damage can occur
before or as a consequence of donor death, during the ische-
mic period or during reimplantation and reperfusion in
the recipient. In an IRI rat model, it has been demon-
strated that hypoxic MSCs can attenuate inflammation
by infusing them a few minutes before the ischemic insult
[19]. Moreover, Stone et al. [16] described that MSCs were
more effective than their extracellular vesicles for restring-
ing lung inflammation when administered via PA before
ischemia and also facilitated damaged organ repairing
when used during EVLP. In line with this, Mordant
et al. [15] demonstrated that MSC therapy was very prom-
ising for reconditioning donor lungs by enhancing the
repairing potential of EVLP. Of note, the main difference
among these studies and ours is that they were designed
with the aim of repairing unacceptable lungs while, in con-
trast, we aimed to preserve donor lung functionality by lim-
iting the ischemic injury.
It is well known that ROS are key players and initiators of
lung IRI as the administration of antioxidant compounds or
antioxidant enzymes, such as SOD and CAT, can prevent tis-
sue damage during reperfusion [35, 42]. In addition, ROS
function as intracellular signaling molecules; thus, regulation
of ROS homeostasis by antioxidant enzymes is important to
trigger redox-specific responses [43]. In this regard, it has
been demonstrated that MSCs are resistant to oxidative stress
because they constitutively express high levels of antioxidant
enzymes and can effectively scavenge ROS [44]. It was also
reported that the anti-inflammatory effect of MSCs in a
model of renal IRI is mediated by suppression of oxidative
stress [45]. Hence, the therapeutic effect of MSCs may be
related, at least in part, to their potential to control oxidative
insults preventing tissue damage. In this way, HUCPVC
administration during donor lung ablation may inhibit
the development of inflammation by blocking ROS-
activated signaling pathways. In fact, here, we found that
HUCPVCs significantly reduced the recruitment of mar-
ginated neutrophils into the interstitium and the alveolar
wall, as demonstrated by a lower number of MPO-
positive cells and a lower MPO activity in the lungs. It is
well known that the prolonged neutrophil transit time













































































Figure 5: Effect of HUCPVCs on oxidative stress parameters during the preservation of donor lungs. Lung biopsies were obtained at the end
of the perfusion from the lungs receiving infusion of vehicle or HUCPVCs. Lung samples from untouched rats (basal) were used as controls.
Protein lysates were prepared and assayed as described in Materials and Methods. (a) Protein carbonyl content. (b) SOD activity. One unit of
SOD is defined as the amount of enzyme that inhibits the reduction of NBT by 50% under assay conditions. (c) CAT activity. One unit of CAT
is defined as the amount of enzyme which breaks down 1 nmol of H2O2 per min under assay conditions. Data are expressed as mean ± S D.
∗p < 0 05, #p < 0 01, and ‡p < 0 001 against the basal group derived from one-way ANOVA after multiple comparisons Tukey post hoc test.
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marginated neutrophil pools [46]. During ischemia, neu-
trophils are recruited from circulation or marginated pools
to the injured lung. In our experimental setting, the oxida-
tive stress triggered during the warm ischemia period may
drive the retention of marginated neutrophils in the lung
tissue. Contrarily, in HUCPVC-treated lungs, which were
protected against oxidative stress, the majority of donor
neutrophils were not retained and were washed from the
lungs during the perfusion.
In conclusion, developing new strategies to improve
donor lung preservation may solve the current organ short-
age by increasing the number of lungs considered acceptable
for transplantation. Anti-inflammatory gene or stem cell
therapies demonstrated great efficacy to reduce IRI and to
recover injured lungs by EVLP. Unlike previous studies,
here, we enhanced the preservation of lungs obtained from
DCD by injecting MSCs during warm ischemia. We have
established that MSCs protect against oxidative stress and
also prevent alveolar wall thickening and neutrophil
recruitment. These data infer that MSCs were able to avoid
lung damage by inhibiting ROS-mediated inflammatory
responses. Most importantly, donor lung function was sig-
nificantly conserved in the lungs receiving MSC therapy.
Accordingly, the implementation of MSC therapy during
lung ablation may have a great clinical impact, as it not
only could be accomplished in small centers, which are
unlikely to establish their own clinical EVLP program, but
also it would improve organ preservation during the whole
procurement procedure.
Data Availability
The data used to support the findings of this study are avail-





















































































































Figure 6: Lung functional data. (a) Pressure-volume curves in mechanically ventilated lungs. Curves were generated by using sequential
pressure steps in which the tidal volume reached at each step was measured by the ventilator. Open symbols represent basal
measurements, and closed symbols represent measurements obtained at the end of the perfusion. Graphs show a baseline vs. endpoint
pressure-volume curve for a representative lung from vehicle and HUCPVC groups. The slope of the pressure-volume curve represents
the lung compliance. (b) Individual changes in lung compliance for vehicle and HUCPVC groups. Lung compliance was determined at
baseline (open symbols) and at the end of the perfusion (closed symbols) from pressure-volume curves data. ∗p < 0 0001 vs. basal derived
from paired t test. (c) Lung compliance reduction expressed as percentage with respect to baseline. ∗p < 0 0001 derived from unpaired t test.
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Supplementary Materials
Figure S1. Mechanical ventilation. (a) Real-time monitoring of
the ventilatory parameters and pressure curves on the digital
display of the ventilator (SomnoSuite™ Small Animal Anes-
thesia System, Kent Scientific). The upper half of the screen
displays the value of the parameters which are being mea-
sured. The lower half of the screen displays a graph of the data.
(b) Graphical representation of pressure vs. time curves in dif-
ferent respiratory cycles. Real-time data was collected in a
computer through the USB port for further analysis. Abbre-
viations: Vt: tidal volume; Ppeak: peak pressure; PEEP: posi-
tive end-expiratory pressure. Figure S2. Hematoxylin and
eosin stained sections obtained at the end of the perfusion
from the lungs receiving infusion of vehicle (left panels) or
HUCPVCs (right panels). Representative images from each
group at ×400 original magnification. Black arrows indicate
the presence of large cells in the lung microvasculature. Sup-
plementary methods: the surgical procedure. Supplementary
Video 1. Showing the lung during ventilation and perfusion
with Steen solution. (Supplementary Materials)
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